Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 5:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 13,738 matching trials from the live ClinicalTrials.gov search.
Filters: Baltimore, Maryland Clear all
Completed No phase listed Observational Accepts healthy volunteers

Study to Evaluate the Performance Validity and Test-Retest Reliability of a Computer-Administered Cognitive Test Battery in Participants With Major Depressive Disorder (MDD)

NCT03014544
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Computer- administered test battery, Examiner- administered test battery
Device
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 59 Years
Enrollment
585 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
20
States / cities
Birmingham, Alabama • Anaheim, California • Beverly Hills, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Nov 5, 2026, 5:03 PM EST
Recruiting Not applicable Interventional

GCC 2546- Motion Management

NCT07398209
View directory record Official record
Conditions
Lung Cancer (NSCLC), Radiation
Interventions
MRI
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Nov 5, 2026, 5:03 PM EST
Completed Phase 1 Interventional

R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia

NCT00004009
View directory record Official record
Conditions
Leukemia
Interventions
tipifarnib
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
3
States / cities
Iowa City, Iowa • Baltimore, Maryland • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Nov 5, 2026, 5:03 PM EST
Completed No phase listed Observational

Breath Carbon Monoxide and Cotinine as Biomarkers to Distinguish Smokers From Nonsmokers

NCT01031121
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 64 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Nov 5, 2026, 5:03 PM EST
Terminated No phase listed Observational

New Enrollment Post-Approval Study of the Argus® II Retinal Prosthesis System

NCT01860092
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Not listed
Lead sponsor
Second Sight Medical Products
Industry
Eligibility
25 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
17
States / cities
Los Angeles, California • Denver, Colorado • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2021 · Synced Nov 5, 2026, 5:03 PM EST
Completed No phase listed Observational Results available

COVID-19 Vaccine Response in Sickle Cell Disease

NCT05139992
View directory record Official record
Conditions
Sickle Cell Disease, COVID-19
Interventions
COVID-19 Vaccine
Biological
Lead sponsor
ASH Research Collaborative
Other
Eligibility
Not listed
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Oakland, California • Washington D.C., District of Columbia • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Nov 5, 2026, 5:03 PM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life

NCT01681992
View directory record Official record
Conditions
Measles, Mumps, Rubella, Measles-Mumps-Rubella Vaccine
Interventions
Priorix, M-M-R II, Varivax, Havrix, Prevnar 13
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
4,538 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Nov 5, 2026, 5:03 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers

A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers

NCT00000871
View directory record Official record
Conditions
HIV Infections
Interventions
MN rgp120/HIV-1 and GNE8 rgp120/HIV-1, MN rgp120/HIV-1 and A244 rgp120/HIV-1, ALVAC-HIV MN120TMG (vCP205), rgp120/HIV-1 SF-2
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2000
U.S. locations
18
States / cities
Birmingham, Alabama • San Francisco, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Nov 5, 2026, 5:03 PM EST
Completed Phase 3 Interventional Results available

Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor

NCT00352534
View directory record Official record
Conditions
Stage I Kidney Wilms Tumor, Stage II Kidney Wilms Tumor, Stage III Kidney Wilms Tumor
Interventions
3-Dimensional Conformal Radiation Therapy, Biospecimen Collection, Chest Radiography, Computed Tomography, Dactinomycin, Doxorubicin Hydrochloride, Echocardiography Test, Magnetic Resonance Imaging, Therapeutic Conventional Surgery, Ultrasound Imaging, Vincristine Sulfate
Radiation · Procedure · Biological + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 29 Years
Enrollment
808 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2026
U.S. locations
210
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 150 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Nov 5, 2026, 5:03 PM EST
Completed Phase 1 Interventional

Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma

NCT00003993
View directory record Official record
Conditions
Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
aldesleukin, bryostatin 1
Biological · Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Nov 5, 2026, 5:03 PM EST
Completed Phase 2 Interventional Results available

Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract

NCT02254421
View directory record Official record
Conditions
Respiratory Syncytial Virus Infection
Interventions
Presatovir, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
11
States / cities
Duarte, California • Chicago, Illinois • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Nov 5, 2026, 5:03 PM EST
Completed Phase 3 Interventional Results available

Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer

NCT02872116
View directory record Official record
Conditions
Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
Interventions
Nivolumab, Ipilimumab, Oxaliplatin, Capecitabine, Leucovorin, Fluorouracil
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
2,031 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
27
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Nov 5, 2026, 5:03 PM EST
Completed Not applicable Interventional

A Comparison of Zidovudine (AZT) and Stavudine in HIV-Infected Patients

NCT00002307
View directory record Official record
Conditions
HIV Infections
Interventions
Stavudine, Zidovudine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
44
States / cities
Tucson, Arizona • Berkeley, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2011 · Synced Nov 5, 2026, 5:03 PM EST
Completed Phase 2 Interventional

Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma

NCT00044564
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Bay 59-8862
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
13
States / cities
La Jolla, California • Muncie, Indiana • New Orleans, Louisiana + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2014 · Synced Nov 5, 2026, 5:03 PM EST
Completed Phase 1 Interventional Results available

An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

NCT04950764
View directory record Official record
Conditions
Primary Biliary Cholangitis, Compensated Cirrhosis, Hepatic Impairment
Interventions
Seladelpar
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
11
States / cities
Chandler, Arizona • Sacramento, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Nov 5, 2026, 5:03 PM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers

Comparison of Tenofovir Vaginal Gel and Film Formulations

NCT02280109
View directory record Official record
Conditions
Healthy, HIV
Interventions
Tenofovir Gel, Tenofovir Film
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Nov 5, 2026, 5:03 PM EST
Recruiting Phase 2 Interventional

Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder

NCT06847399
View directory record Official record
Conditions
Obesity and Overweight, Binge Eating Disorder
Interventions
Tirzepatide, Lisdexamfetamine Dimesylate, Guided self-help cognitive behavioral therapy, Placebo (oral), Placebo (injection)
Drug · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Nov 5, 2026, 5:03 PM EST
Completed Not applicable Interventional Results available

Metabolic Impact of Intermittent CPAP

NCT02824263
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
CPAP withdrawal
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
20 Years to 75 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 5, 2026, 5:03 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Anti-MAG First Administration to Human

NCT00622609
View directory record Official record
Conditions
Cerebrovascular Accident
Interventions
GSK249320A, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Nov 5, 2026, 5:03 PM EST
Completed Phase 2 Interventional Results available

Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer

NCT00423293
View directory record Official record
Conditions
Anal Cancer
Interventions
fluorouracil, mitomycin C, Intensity-modulated radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
169
States / cities
Tucson, Arizona • Auburn, California • Burbank, California + 128 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Nov 5, 2026, 5:03 PM EST
Active, not recruiting Phase 2 Interventional Results available

Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC

NCT02259621
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Nivolumab, Carboplatin, Paclitaxel, Ipilimumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
4
States / cities
Baltimore, Maryland • New York, New York • Edmonds, Washington
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Nov 5, 2026, 5:03 PM EST
Active, not recruiting Phase 3 Interventional

A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

NCT05976243
View directory record Official record
Conditions
Chronic Inducible Urticaria
Interventions
Remibrutinib, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
25
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 5, 2026, 5:03 PM EST
Completed Phase 2 Interventional Results available

Baked Egg or Egg Oral Immunotherapy for Children With Egg Allergy

NCT01846208
View directory record Official record
Conditions
Food Allergy
Interventions
Egg Oral Immunotherapy, Baked Egg
Drug
Lead sponsor
Hugh A Sampson, MD
Other
Eligibility
3 Years to 16 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
5
States / cities
Little Rock, Arkansas • Denver, Colorado • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2019 · Synced Nov 5, 2026, 5:03 PM EST
Completed Phase 2 Interventional Results available

A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

NCT00676715
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Placebo, Ocrelizumab, Avonex
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2023
U.S. locations
26
States / cities
Phoenix, Arizona • Berkeley, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2024 · Synced Nov 5, 2026, 5:03 PM EST